Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||FGFR2 - NRAP|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - NRAP FGFR2 N550K||intrahepatic cholangiocarcinoma||resistant||Futibatinib||Case Reports/Case Series||Actionable||In a Phase I trial, a patient with intrahepatic cholangiocarcinoma, harboring an FGFR2-NRAP fusion responded to TAS-120 for 17.2 months before progressing due to an acquired FGFR2 N550K mutation, detected in cell-free DNA and the tumor biopsy (PMID: 31109923; NCT02052778).||31109923|
|FGFR2 - NRAP FGFR2 N549K FGFR2 V564L||cholangiocarcinoma||predicted - resistant||Infigratinib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-NRAP fusion experienced disease progression after seven months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, N549K and V564L (PMID: 34250419).||34250419|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|